Glenmark Pharmaceuticals has launched the innovative lung cancer drug Tevimbra (tislelizumab) in India, following its approval by the Central Drugs Standard Control Organization (CDSCO). Tevimbra is an immuno-oncology therapy developed by BeiGene (now BeOne Medicines) and marks Glenmark’s strategic entry into advanced cancer care.

Key highlights

Approved for NSCLC and ESCC treatment

• Tevimbra is indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy.

• It is also approved as second-line monotherapy for NSCLC and esophageal squamous cell carcinoma (ESCC).

Innovative immuno-oncology mechanism

• The active ingredient, tislelizumab, is a PD-1-blocking IgG4 monoclonal antibody.

• It enhances immune response by preventing tumor escape via Fcγ receptor binding minimization.

Developed by BeiGene and marketed globally

• Tevimbra is the flagship immunotherapy in BeOne’s solid tumor portfolio.

• Already approved in key global markets including the US, EU, China, and Australia.

• Reported global sales of $625 million in 2024 (~₹5,300 crore).

Glenmark’s oncology expansion

• Glenmark partnered with BeiGene in 2023 to market Tevimbra and Zanubrutinib in India.

• Launch signals Glenmark’s deeper commitment to accessible, advanced cancer therapies.

Statements from leaders
 “Immuno-oncology offers a promising future for the treatment of advanced cancers. Our foray into this space is a significant step toward building a world-class oncology portfolio that is innovative, inclusive, and life-changing,” said Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals.With the introduction of Tevimbra, Glenmark strengthens its oncology pipeline and reinforces its commitment to making cutting-edge cancer therapies accessible in India.